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Purpose: To identify the genetic defect in a Hutterite population from northern Alberta with Usher syndrome type I.
Methods: Complete ophthalmic examinations were conducted on two boys and two girls from two related Hutterite
families diagnosed with Usher syndrome type I. DNA from patients and their parents was first evaluated for a mutation
in exon 10 of the protocadherin-related 15 (PCDH15) gene (c.1471delG), previously reported in southern Alberta Hutterite
patients with Usher syndrome (USH1F). Single nucleotide polymorphic linkage analysis was then used to confirm another
locus, and DNA was analyzed with the Usher Chip v4.0 platform.
Results: Severe hearing impairment, unintelligible speech, and retinitis pigmentosa with varying degrees of visual acuity
and visual field loss established a clinical diagnosis of Usher syndrome type I. The patients did not carry the exon 10
mutation in the PCDH15 gene; however, with microarray analysis, a previously reported mutation (c.52C>T; p.Q18X)
in the myosin VIIA (MYO7A) gene was found in the homozygous state in the affected siblings.
Conclusions: The finding of a MYO7A mutation in two related Hutterite families from northern Alberta provides evidence
of genetic heterogeneity in Hutterites affected by Usher syndrome type I.
Usher  syndrome  (USH)  is  an  autosomal  recessive
disorder, characterized by bilateral hearing loss and retinitis
pigmentosa  (RP).  As  the  most  frequent  cause  of
deafblindness, the clinical features of USH are heterogeneous
along  with  the  underlying  genetics.  Clinical  examination
defines  three  types:  Usher  syndrome  type  I  (USH1)  with
severe to profound congenital hearing impairment, vestibular
dysfunction, and retinal degeneration beginning in childhood;
type II (USH2) with moderate to severe hearing impairment,
normal  vestibular  function,  and  later  onset  retinal
degeneration  [1];  and  type  III  (USH3)  with  progressive
hearing loss and variable age of onset of retinal degeneration
[2]. Some cases are not easily classifiable under these present
categories  and  could  be  categorized  as  atypical  USH
syndrome [3].
The Hutterites are a genetically isolated population that
has lived on the North American prairies since the late 1800s
[4].  Currently,  most  Canadian  Hutterites  live  in  colonies
formed  in  Alberta,  Saskatchewan,  and  Manitoba  in  1918.
Since the three groups were established in North America (the
Schmiedeleut, Dariusleut, and Lehrerleut), the leuts (groups)
have  maintained  separate  identities  with  the  majority  of
marriages occurring between individuals from the same leut.
Lowry and colleagues [5] hypothesized that the lifestyle and
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nutrition of Hutterite communities might reduce the frequency
of congenital anomalies, while consanguinity might serve to
increase their frequency. Because of intermarriage within the
Hutterite population, rare alleles causing autosomal recessive
conditions were likely introduced into the population by one
or, at most, a few ancestors. A larger number of monogenic
disorders and fewer multifactorial, congenital anomalies are
found in the Hutterite population [5].
A mutation in exon 10 of the protocadherin-related 15
(PCDH15) gene (c.1471delG) was previously reported in the
Hutterite population of southern Alberta [6]. Our colleagues
from southern Alberta were not aware of other individuals
with  Usher  syndrome  in  the  province  (R.  Brian  Lowry,
Alberta  Children's  Hospital,  Calgary,  Alberta,  Canada,
January 2012). As the Hutterite populations are genetically
isolated,  we  hypothesized  a  founder  effect,  that  the  same
mutation would be carried by all Hutterites. Here, we describe
two  Hutterite  families  from  northern  Alberta  with  Usher
syndrome type I who did not carry a mutation in exon 10 of
PCDH15 but did carry a mutation in exon 3 of the myosin
VIIA  (MYO7A)  gene,  providing  evidence  of  genetic
heterogeneity in Alberta Hutterites with Usher syndrome type
I.
METHODS
This study was conducted under the tenets of the Declaration
of Helsinki and was approved by the Health Research Ethics
Board of the University of Alberta. Informed written consent
was obtained from the subjects.
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1379Family data: Patients, two boys and two girls, from two
related Hutterite families, were referred to the Department of
Ophthalmology, University of Alberta, Canada. A detailed
medical history was obtained. Ocular examinations included
the measurement of visual acuity, retinoscopy, funduscopy
with photographic documentation, and Goldmann visual field
examination. DNA was prepared, according to a standard
protocol,  from  peripheral  blood  samples  taken  from  the
parents and all the siblings of the two families. Pure tone
audiometry results for individual II:4 at the age 6 and 7 were
obtained from the referring physician.
Mutation analysis: Fluorescently labeled primers were
used to amplify exon 10 of PCDH15; the molecular size of
the amplicon was determined with BI 3100 DNA sequencing
and GeneMapper 4.0 software (Carlsbad, CA). Fluorescent
microsatellite marker genotyping is accurate down to the base
pair level. Individuals carrying a deletion in exon 10 would
have an amplicon of decreased size compared to wild-type and
all amplicons were sequenced for additional confirmation.
Single nucleotide polymorphic (SNP) linkage analysis was
first used to confirm another presumed locus for the disorder.
DNA was then further analyzed using the Usher Chip v4.0
platform [7]. A pathologic mutation on the array (c.52C>T;
p.Q18X) was confirmed to be present with standard Sanger
sequencing of DNA from the patients and their parents.
RESULTS
Clinical findings: Two boys and two girls from two related
Hutterite  families  were  diagnosed  with  Usher  syndrome
(Figure  1).  All  four  patients  had  prelingual,  bilateral
sensorineural  hearing  loss,  and  delayed  development  of
walking in early childhood. The pure tone audiometry results
from individual II:4 showed hearing thresholds of 25, 60, 75,
75, and 80 dB at 0.25, 0.5, 1, 2, and 4 kHz, respectively, in the
right ear, and 35, 65, 75, 55, and 65 dB in the left ear. There
was no change in the thresholds one year later. The patients
did not develop intelligible speech, and hearing aids were not
effective. At the time of referral, all showed evidence of RP.
Individuals II:1 and II:2 showed bilateral nasal loss of the
visual field, and bone spicules in the nasal fundus at the age
of 18 and 10, respectively. Subject II:3 showed bilateral bone
spicules in the fundus, and only 20 degrees of visual field was
preserved in both eyes by age 13. Subject II:4 showed bilateral
nasal loss of the visual field and bone spicules in both eyes at
age  9.  The  ocular  findings  of  the  Hutterite  patients  from
northern  Alberta  are  listed  in  Table  1.  Characteristic
Goldmann visual fields and fundus photographs are shown in
Figure 2 and Figure 3, respectively. The patients’ parents all
had normal fundus examinations and normal visual fields.
While asymptomatic, no formal tests of balance and hearing
were obtained.
Mutation analysis: No difference in the size of the amplicon
of  exon  10  of  PCDH15  was  observed  in  the  affected
Figure 1. Pedigree of Hutterite families. MYO7A mutation c.57C>T (-), normal allele (+).
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1380individuals  compared  to  unaffected  relatives  or  wild-type
controls. In addition, direct sequencing of this amplicon failed
to reveal a mutation in any of the four siblings (data not
shown). Further, SNP linkage analysis demonstrated linkage
to the 11q region, the locus for USH1B. With microarray
analysis  [7],  a  point  mutation  (c.52C>T;  p.Q18X)  was
revealed  in  exon  3  of  the  MYO7A  gene  (NM_000260.3;
NP_000251.3)  segregating  in  both  families.  All  affected
siblings  were  homozygous  for  the  mutation,  and  all  four
parents were heterozygous (Figure 1).
DISCUSSION
Usher  syndrome  is  the  most  common  cause  of  bilateral
hearing  loss  and  RP,  accounting  for  more  than  50%  of
individuals who are both deaf and blind [8,9], about 18% of
RP cases [10], and 5% to 9% of all cases of childhood deafness
[11,12]. The prevalence of Usher syndrome varies from 3.2
to  6.2/100,000  depending  on  the  study  [8,10,13-15].  The
diagnosis is made primarily based on the clinical findings.
While auditory and vestibular functions are the distinguishing
features of the three different types, RP is the main ophthalmic
manifestation shared by all three. Usher patients experience
progressive photoreceptor degeneration (RP), which leads to
loss of peripheral vision. Clinical symptoms may vary and
include  night  blindness  (nyctalopia)  with  elevated  dark
adaptation  thresholds,  abnormal  electroretinographic
responses,  visual  field  constriction,  abnormal  retinal
pigmentation  including  peripheral  bone  spicules,  arterial
narrowing, and optic nerve pallor, and a predisposition to
myopia and posterior subcapsular cataracts [16]. Alteration in
the  morphogenesis  and  stability  of  stereocilia  results  in
sensorineural hearing loss and may also cause balance defects
[17].
Usher syndrome type I is the most severe form of this
disease.  USH1  patients  suffer  from  severe  to  profound
prelingual  and  bilateral  sensorineural  hearing  loss.  These
individuals  are  either  born  completely  deaf  or  experience
hearing impairment within the first year of life and usually do
not develop speech. Most, but not all, USH1 patients exhibit
severe dysfunction of the vestibular system from birth [3].
Children may manifest a delay in gross motor development;
they will sit independently and walk significantly later than
normal. The onset of RP in USH1 occurs before puberty and
leads to visual field constriction and total blindness afterward.
In  our  Hutterite  families,  none  of  the  patients  developed
intelligible speech, indicating prelingual, possibly congenital
hearing loss. They all had signs of RP at an early age (in their
teens). The history of delayed development of walking was
also a clue to vestibular dysfunction and allowed us to assign
the  diagnosis  of  USH1  in  these  families;  however,  the
TABLE 1. CLINICAL FEATURES OF PATIENTS WITH USHER SYNDROME TYPE I
Patient Age Vision Refraction Visual field Fundus
II-1 18 OD:20/25 Plano Nasal loss Optic nerve head drusen
    OS:20/25 Plano Nasal loss Optic nerve head drusen
II-2 10 OD:20/40 −4.50+0.50×100 Nasal loss See Figure 3
    OS:20/50 −4.50+0.50×100 Nasal loss See Figure 3
II-3 13 OD:20/25 −1.00+1.75×95 See Figure 2 Bone spicules
    OS:20/50 −1.50+1.50×43 See Figure 2 Bone spicules
II-4 9 OD:20/50 −0.50+2.00×80 Nasal loss Bone spicules
    OS:20/200 −0.50+1.75×83 Nasal loss Bone spicules
Figure 2. Visual field of patient II:3, age 13. Constricted visual field, central 20 degrees preserved (OU).
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1381audiometric results from one patient showed lower hearing
thresholds than reported in the literature for USH1. Pakarinen
et al. [18] found mean hearing thresholds of about 90, 100,
105, and 110 dB at 0.25, 0.5, 1, and 2 kHz, respectively, in 79
patients with Usher syndrome type I. Wagenaar et al. [19]
found minimum hearing thresholds of 80, 95, 120, and 120 dB
at 0.25, 0.5, 1, and 2 kHz, respectively, in patients with type
I. The reported pure tone average in patients with type II is
between 40 and 90 dB [18,20]. The hearing pattern in case II:
4 from our families was similar to type II; however, although
she began to wear hearing aids at the age of 2, she did not
develop  intelligible  speech,  and  her  hearing  remained
relatively stable. These findings still confirmed the clinical
diagnosis of USH1. There may be genetic modifiers in this
Hutterite family that result in the observed differences in
hearing. Further study is necessary with more comprehensive
evaluations of hearing and vestibular function.
To  date,  there  are  five  known  USH1  genes:  MYO7A
(USH1B),  cadherin-23  (CDH23;  USH1D),  PCDH15
(USH1F), Usher syndrome type 1C (USH1C; USH1C), and
SANS (USH1G) [21]. The myosin VIIa gene (MYO7A) was
the first identified USH gene [22], and at least 29% to 50% of
the known USH1 cases in different populations are caused by
mutations in MYO7A [23-26]. Mutations in the MYO7A gene
are also associated with an autosomal recessive form of non-
syndromic  hearing  loss  known  as  DFNB2,  and  with  an
autosomal  dominant  form  of  hearing  loss  designated
DFNA11.  The  MYO7A  gene  encodes  an  unconventional
myosin. Myosins are motor molecules with highly divergent
tails  that  move  along  actin  filaments.  This  movement  is
presumed  to  enable  them  to  transport  cargo  [22].  In  the
families in this study, a point mutation in the MYO7A gene (c.
52C>T; Q18X) was carried in the homozygous state in all
affected individuals. The mutation creates a stop mutation and
truncates the protein product. This could explain the severe
phenotype  in  all  four  patients  and  the  lack  of  apparent
phenotypic variability. Other mutations in MYO7A have been
reported to cause a less severe phenotype with significant
intrafamilial variability of the trait, such as the c.1935G>A
mutation that alters the splicing of exon 16, with exclusion
[27].
In summary, we searched for a deletion in exon 10 of the
PCDH15  gene,  previously  identified  in  the  Hutterites;
however,  none  was  found  in  two  related  families  from
northern Alberta. The finding of mutation in MYO7A in these
families  provides  evidence  of  genetic  heterogeneity  in
Hutterites affected by Usher syndrome type I.
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